Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1992 2
1996 1
1997 2
1998 1
1999 1
2000 3
2001 1
2002 3
2003 1
2004 1
2005 2
2006 3
2007 1
2008 4
2010 1
2011 2
2012 3
2014 1
2015 1
2016 1
2021 1
2022 1
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.
Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss J, Hava DL, Janku F. Luke JJ, et al. Among authors: riese rj. Clin Cancer Res. 2023 Jul 5;29(13):2435-2444. doi: 10.1158/1078-0432.CCR-23-0118. Clin Cancer Res. 2023. PMID: 37227176 Free PMC article. Clinical Trial.
Emerging roles for cysteine proteases in human biology.
Chapman HA, Riese RJ, Shi GP. Chapman HA, et al. Among authors: riese rj. Annu Rev Physiol. 1997;59:63-88. doi: 10.1146/annurev.physiol.59.1.63. Annu Rev Physiol. 1997. PMID: 9074757 Review.
Proteases involved in MHC class II antigen presentation.
Villadangos JA, Bryant RA, Deussing J, Driessen C, Lennon-Duménil AM, Riese RJ, Roth W, Saftig P, Shi GP, Chapman HA, Peters C, Ploegh HL. Villadangos JA, et al. Among authors: riese rj. Immunol Rev. 1999 Dec;172:109-20. doi: 10.1111/j.1600-065x.1999.tb01360.x. Immunol Rev. 1999. PMID: 10631941 Review.
Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.
Puurunen MK, Vockley J, Searle SL, Sacharow SJ, Phillips JA 3rd, Denney WS, Goodlett BD, Wagner DA, Blankstein L, Castillo MJ, Charbonneau MR, Isabella VM, Sethuraman VV, Riese RJ, Kurtz CB, Brennan AM. Puurunen MK, et al. Among authors: riese rj. Nat Metab. 2021 Aug;3(8):1125-1132. doi: 10.1038/s42255-021-00430-7. Epub 2021 Jul 22. Nat Metab. 2021. PMID: 34294923 Clinical Trial.
Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.
Puurunen MK, Vockley J, Searle SL, Sacharow SJ, Phillips JA 3rd, Denney WS, Goodlett BD, Wagner DA, Blankstein L, Castillo MJ, Charbonneau MR, Isabella VM, Sethuraman VV, Riese RJ, Kurtz CB, Brennan AM. Puurunen MK, et al. Among authors: riese rj. Nat Metab. 2022 Sep;4(9):1214. doi: 10.1038/s42255-022-00635-4. Nat Metab. 2022. PMID: 35974248 No abstract available.
36 results